Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4792692 | 0.89 | BACE1 (0.30) | — | |
| SCHEMBL4867741 | 0.82 | TAAR1 (0.35) | — | |
| SCHEMBL4660173 | 0.79 | KDM4E (0.39) | — | |
| SCHEMBL5944772 | 0.77 | — | — | |
| SCHEMBL4872156 | 0.75 | NQO2 (0.39) | — | |
| SCHEMBL4792743 | 0.74 | MAPT (0.33) | POLB | |
| SCHEMBL14188890 | 0.69 | ALDH1A1 (0.41) | POLB | |
| SCHEMBL20998213 | 0.64 | — | — | |
| SCHEMBL20703436 | 0.64 | — | — | |
| SCHEMBL25392849 | 0.64 | TACR1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1606280-A4 | TETRAHYDROPYRANYL CYCLOPENTYL HETEROCYLIC AMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2008-12-24 | — | — | EP | disclosed |
| US-7393844-B2 | Tetrahydropyranyl cyclopentyl heterocyclic amide modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7393844-B2 | Tetrahydropyranyl cyclopentyl heterocyclic amide modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-20060178363-A1 | Tetrahydropyranyl cyclopentyl heterocyclic amide modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2006-08-10 | — | — | US | disclosed |
| EP-1606280-A2 | TETRAHYDROPYRANYL CYCLOPENTYL HETEROCYLIC AMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co. Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004082616-A2 | TETRAHYDROPYRANYL CYCLOPENTYL HETEROCYLIC AMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO. INC. (US) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178363-A1 | Tetrahydropyranyl cyclopentyl heterocyclic amide modulators of chemokine receptor activity | CCR1, CCR2, CCR5 | POLB 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.